Stereochemistry | ABSOLUTE |
Molecular Formula | C26H40O3 |
Molecular Weight | 400.594 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@]3([H])[C@@]4([H])CCC(=O)C=C4C[C@@H](C)[C@@]23[H]
InChI
InChIKey=YHLLSSBURKVUEG-YFGHHJRWSA-N
InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-22-25-17(2)15-18-16-19(27)9-10-20(18)21(25)13-14-26(22,23)3/h16-17,20-23,25H,4-15H2,1-3H3/t17-,20+,21-,22+,23+,25-,26+/m1/s1
Molecular Formula | C26H40O3 |
Molecular Weight | 400.594 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Trestolone is a synthetic androgen that inhibits the release of follicle-stimulating hormone and impairs spermatogenesis. Luteinizing hormone is also suppressed, which cuts production of testosterone. The azoospermia and oligospermia are reversible after discontinuation of trestolone. Trestolone has androgenic and anabolic properties and loss of secondary sex characteristics is not seen. Like testosterone, trestolone undergoes enzymatic aromatization to an estrogen. The use of trestolone instead of testosterone for androgen replacement therapy could have health-promoting effects by reducing the occurrence of prostate disease. Trestolone had been in phase II clinical trial for the andropause control. However, this development was discontinued.